Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced today that Tampa General Hospital Cancer Institute (TGH Cancer Institute) has joined Caris’ Precision Oncology Alliance (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
Established in 2021 and building on the success of the Tampa General Hospital oncology program, the TGH Cancer Institute provides comprehensive care via state-of-the-art therapies and advanced diagnostic imaging and molecular tools. As part of an academic medical center, TGH Cancer Institute’s team of surgical, medical and radiation oncologists, together with other medical specialists, take a multidisciplinary approach, combining access to cutting-edge clinical trials and therapies with compassionate and personalized care focusing on the whole patient. TGH Cancer Institute is rated among the top 10% of U.S. hospitals for cancer care, according to U.S. News & World Report‘s 2021-2022 rankings.
“TGH Cancer Institute is thrilled to join the Caris Precision Oncology Alliance and partner with key academic and clinical institutions similarly dedicated to advancing precision medicine and biomarker research,” said Eduardo M. Sotomayor, M.D., Director, TGH Cancer Institute. “Our goal is to bring world-class, leading-edge and innovative cancer care to the Tampa Bay region, and the POA offers our team access to a collaborative research network focused on identifying predictive and prognostic markers. As a physician-scientist myself, I know that access to advanced research and innovations make a significant impact in improving the outcomes and clinical care of patients with cancer.”
TGH Cancer Institute’s nationally renowned cancer physicians and physician-scientists offer a highly coordinated range of multidisciplinary specialties such as hematologic malignancies, neuro-oncology, thoracic, breast, colorectal, urologic, head and neck and gynecologic oncology.
“TGH Cancer Institute’s focus on innovation and research builds upon the POA’s goal to promote broad-based collaboration among our member institutions in precision oncology research to improve outcomes of all patients with cancer,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “We are excited to welcome them to the POA, and look forward to helping them advance cancer care in the region.”
“Partnering with Caris will not only allow us to integrate state-of-the-art somatic tumor profiling for more precise diagnosis and treatment into clinical care, but also elevate the functionality of our rapidly growing biorepository and other core resources,” said Matthew L. Anderson, M.D., Ph.D., Associate Director for Shared Resources, TGH Cancer Institute and Professor in the Department of Obstetrics and Gynecology for the USF Health Morsani College of Medicine. “Access to molecularly characterized specimens will be a powerful tool we intend to leverage as we grow our translational and basic research portfolio.”
In addition to serving the greater Tampa Bay region on the west coast of Florida, Tampa General is bringing together a network of cancer services to link patients on Florida’s east coast to highly complex care. Patients in the Palm Beach and Treasure Coast area can receive care in their own community and when needed, access Tampa General for advanced treatment and services.
“Joining the POA will provide the TGH Cancer Institute with broader resources, and bring groundbreaking cancer care to patients on both the east and west coast of Florida,” said Abraham Schwarzberg, M.D., Chief of Oncology and Senior Vice President of Network Development, Tampa General. “This is exactly the type of alliance that will help us move forward in our vision to be the safest and most innovative academic health system in America.”
The Caris Precision Oncology Alliance includes 59 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1 million data points per patient.